Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

News, archive: January 2020

1/31/2020 Database Update: API Import to Russia (November 2019)

Between January and November 2019, Russia imported 118 bln RUB worth of APIs (customs clearance prices, VAT included), which is in monetary terms (rubles) 35.6% higher than that of the same period in 2018. The dynamics in physical terms (tons) are +12.9%, with 12 thousand tons. Price rises are obviously the main growth factor here.

1/29/2020 Database Update: Import of Veterinary Drugs, Feed Supplements, and Veterinary APIs to Russia (November 2019)

Between January and November 2019, Russia imported 33.1 bln RUB worth of veterinary drugs (customs clearance prices, VAT included), which is surprisingly higher than the import of feed supplements (32.5 bln RUB). The reason lies both in the sudden growth of veterinary drug imports (+41.7% in rubles) and the significant drop in feed supplement imports (-7.7%). The import of veterinary APIs still has the highest dynamics among the veterinary product imports (+66.3% and 2.9 bln RUB).

1/28/2020 Database Update: Pharmaceutical Drug Import to Russia (November 2019)

Between January and November 2019, Russia imported 703.9 bln RUB worth of ready-made pharmaceutical drugs (customs clearance prices, VAT included), which is in monetary terms (rubles) 47.7% higher than that of the same period in 2018, and 116.3 bln RUB worth of in-bulk drugs, with the dynamics in monetary terms of +18.9%.